Your browser doesn't support javascript.
loading
Association between high-threshold practices and buprenorphine treatment termination.
Lyle, Valencia; Harris, Samantha; Heidari, Omeid; Boulton, Kathryn; Hulsey, Eric; Saloner, Brendan; Gibbons, Jason.
Afiliação
  • Lyle V; Bureau of Community and Health Systems, Michigan Department of Licensing and Regulatory Affairs, 611 W. Ottawa St, Lansing, MI 48909, USA. Electronic address: lylev@michigan.gov.
  • Harris S; Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, 624 N. Broadway, Baltimore, MD 21205, USA.
  • Heidari O; Department of Child, Family, and Population Health Nursing, School of Nursing, University of Washington, 1959 NE Pacific St, Seattle, WA 98195, USA.
  • Boulton K; Overdose Prevention Program, Vital Strategies, 100 Broadway, 4(th) Floor, New York, NY 10005, USA.
  • Hulsey E; Overdose Prevention Program, Vital Strategies, 100 Broadway, 4(th) Floor, New York, NY 10005, USA.
  • Saloner B; Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, 624 N. Broadway, Baltimore, MD 21205, USA.
  • Gibbons J; Department of Health Systems, Management and Policy, Colorado School of Public Health, University of Colorado, Denver, 13001 E 17th Pl B119, Aurora, CO 80045, USA.
Int J Drug Policy ; 124: 104318, 2024 Feb.
Article em En | MEDLINE | ID: mdl-38232439
ABSTRACT

BACKGROUND:

Regular counseling and frequent drug testing are common requirements for patients with opioid use disorder in buprenorphine treatment. State policies throughout the United States often reinforce these high-threshold practices, as was the case with Michigan, USA.

METHODS:

We sought to explore the association between counseling requirements, drug testing practices, and buprenorphine treatment termination rates through administering a survey to buprenorphine prescribers in Michigan.

RESULTS:

In our sample of 377 prescribers, we found associations between high-threshold practices like drug testing at every clinical visit and requiring counseling and buprenorphine treatment termination rates. Relative to prescribers who randomly drug tested, drug tested at fixed intervals, or did not require any drug testing, prescribers who drug-tested patients at every visit were 38% more likely to terminate treatment. Prescribers who required counseling were 33% more likely to terminate treatment than those who did not require counseling.

CONCLUSION:

With the elimination of the USA Drug Enforcement Administration X-waiver in December 2022, state policies need to minimize high-threshold practices that reduce buprenorphine treatment continuity and undermine an effective response to the overdose crisis.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Buprenorfina / Transtornos Relacionados ao Uso de Opioides Tipo de estudo: Risk_factors_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Buprenorfina / Transtornos Relacionados ao Uso de Opioides Tipo de estudo: Risk_factors_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article